Lung Cancer B7391003

May 09, 2017

Sponsor: Pfizer

Number: B7391003 

Eligible patients who enroll in the study will be randomly assigned (by chance) to this multinational, double-blind (There will be two groups, the patient and the doctors will not know which group the patient is in. The key that identifies the subjects and which group they belonged to is kept by a third party, and is not revealed to the researchers until the study is over), parallel-group Phase 3 (Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely) clinical trial evaluating the efficacy and safety of Bevacizumab-Pfizer plus Paclitaxel and Carboplatin versus Bevacizumab-EU plus Paclitaxel and Carboplatin in first-line treatment for patients with advanced (unresectable/unable to be removed by surgery, locally advanced, recurrent or metastatic/development of secondary malignant growths at a distance from a primary site of cancer) non-squamous NSCLC.

Who’s eligible:

  • Patients must be newly diagnosed with Stage IIIB or IV non-small cell lung cancer (according to Revised International System for Staging Lung Cancer criteria of 2010) or recurrent non-small cell lung cancer (NSCLC).
  • The patient must have histologically (tissue microscopically examined) or cytologically (fluid cells microscopically examined) confirmed diagnosis of predominately non-squamous NSCLC.
  • Be eligible to receive study treatment of Bevacizumab, Paclitaxel, and Carboplatin based on local standard of care, for the treatment of advanced or metastatic non-squamous NSCLC.
  • This study is for patients age 18 and older.

Available at: The Hospital of Central Connecticut- The Cancer Center of Central Connecticut.

Cancer Clinical Research Office